Studies Conflict on Ranibizumab's Stroke Risk

In a new study, stroke occurred in 6.6% of the ranibizumab-treated group, compared with 7.0% of the controls matched by sociodemographic factors and comorbidities and 6.7% of the controls matched by sociodemographic factors only. These differences were not statistically significant.

Insufficient data has hampered efforts to come to a definitive conclusion about whether intravitreal treatment with anti-vascular endothelial growth factor (VEGF) agents increases the risk of stroke. However, a recent study based on South Korean registry data provided additional evidence that intravitreal treatment with ranibizumab (Lucentis/Roche) is not associated with a statistically significant difference in the rate of stroke in patients with wet age-related macular degeneration (AMD).

Soon after Genentech introduced Lucentis in 2006, it warned of an increased risk of stroke from the 0.5mg dose approved by the US Food and Drug Administration (FDA) compared with the 0.3mg dose, which was also studied. Interim analysis of SAILOR study data showed a 1.2% risk of stroke in the 0.5mg arm and a 0.3% risk in the 0.3mg arm (P = 0.02). Since then, a meta-analysis of five Lucentis trials found some evidence of increased risk of cerebrovascular accidents for ranibizumab vs. control or for 0.5mg Lucentis vs. 0.3mg Lucentis.

Moreover, analysis of data on nearly 58,000 Canadian patients with AMD or macular edema treated with Lucentis or bevacizumab (Avastin/Roche) showed an increase in stroke risk from 10.7 to 18.6 per 1,000 patients annually after initiation of treatment with either intravitreal anti-VEGF agent. The increase, which was particularly pronounced for ischemic stroke, exceeded trends due to aging, occurred with each agent, and did not occur in controls who had cataract surgery. Another analysis found an increased risk of hospitalization for ischemic stroke in the second month after Lucentis treatment for wet AMD.

However, other studies did not support these findings. A time series analysis of Canadian data found that the rapid adoption of anti-VEGF therapy for AMD was not associated with an increased rate of hospital admission for stroke. Moreover, a recently published analysis of Medicare data showed that the introduction of anti-VEGF agents did not increase the risk of stroke in patients with wet AMD.

A Canadian case-control study found no increased risk of stroke in wet AMD patients treated with Avastin, and a study of Canadian retinal disease patients hospitalized for ischemic stroke found they were no more likely to have received intravitreal Avastin or Lucentis than controls.

The South Korean study provides additional support for the conclusion that intravitreal Lucentis does not increase stroke risk in wet AMD patients. This study used national registry data on more than one million random subjects to compare a Lucentis-treated group with two matched control groups.

The treated group included 467 wet AMD patients who received intravitreal Lucentis between 2009 and 2013. The first control group included 2,330 randomly selected patients matched to the treated group by sociodemographic factors and comorbidities (hypertension, atrial fibrillation, and Charlson comorbidities index score). Another control group of 2,331 patients were matched by sociodemographic factors only. Patients were tracked until 2013, and data were analyzed by using Cox proportional hazard regression.

The South Korean team found that stroke occurred in 6.6% of the Lucentis-treated group, compared with 7.0% of the controls matched by sociodemographic factors and comorbidities and 6.7% of the controls matched by sociodemographic factors only. These differences were not statistically significant.

Moreover, multivariable Cox regression indicated that the incidence of stroke was similar for the Lucentis group and the control groups. For the Lucentis group compared with the control group matched by sociodemographic factors and comorbidities, the hazard ratio (HR) was 0.88 (95% confidence interval (CI), 0.60—1.30). For the Lucentis group compared with the control group matched by sociodemographic factors only, the HR was 0.95 (CI, 0.64–1.41).

As a result, the South Korean team concluded that Lucentis treatment for wet AMD did not increase the risk of stroke compared with the risk for matched controls.

The study, “Intravitreal ranibizumab therapy for neovascular age-related macular degeneration and the risk of stroke: a national sample cohort study,” was published in the November, 2016, issue of Retina.

Related Coverage:

Research Warns Against Bevacizumab for AMD Shortly After Stroke

No Tool Yet to Identify Visual Impairments after Strokes

Treating Wet Age-Related Macular Degeneration Making Great Strides